PATIENTS AND METHODS : Patients with HER2 -positive locally advanced breast cancer or MBC were treated with 3.6 mg/kg T- DM1 plus pertuzumab ( 840-mg loading dose , then 420 mg subsequently ) once every 3 weeks .